| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Moonlake Immunotherapeutics (MLTX) has 8 insiders with recent SEC Form 4 filings, including 7 buys and 0 sells. MLTX is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| Other | 2.82M | $56.21M | -150,000 | |
| ? | 1.99M | $39.68M | - | |
| CFO | 1.15M | $22.98M | -17,876 | |
| CEO | 520.3K | $10.35M | - | |
| Dir | 22.2K | $441.7K | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Mar 21, 2023 | Chen Bihua56 | - | Buy | 827,100 | $20.28 | $16,774,845.82 | +6.4% | +20.1% | +124.9% | |
| Apr 5, 2022 | Chen Bihua56 | 10% Owner | Buy | 2,850,000 | $10.00 | $28,500,000.00 | New | -57.6% | +53.3% | |
| Oct 22, 2020 | Chen Bihua56 | CEO And Chairman | Buy | 430,000 | $10.00 | $4,300,000.00 | New | - | - | |
| Oct 22, 2020 | Helix Holdings LLC | Director, 10% Owner | Buy | 430,000 | $10.00 | $4,300,000.00 | New | - | - |